Skip to main content
Premium Trial:

Request an Annual Quote

Lineagen Taps PWNHealth to Increase Consumer Access to Genetic Tests

NEW YORK (GenomeWeb) – Lineagen said today that it is partnering with telemedicine company PWNHealth to expand access to its clinical genetic tests through a consumer-initiated model.

Lineagen provides testing services to individuals with developmental delay and autism spectrum disorder, including a chromosomal microarray assay called FirstStep Plus and a whole-exome sequencing test called NextStep Plus. These tests require an order from a licensed healthcare provider.

Through its partnership with PWNHealth, Lineagen will develop a digital platform that streamlines the ordering process for its tests while maintaining the requisite oversight and guidance of licensed clinical providers and genetic counselors, Lineagen said.

"Time matters for these kids and their families," Lineagen CEO Michael Paul said in a statement. "Lineagen is committed to helping reduce the diagnostic and clinical odyssey experienced by many individuals and families across the autism and neurodevelopmental disorder spectrum. Our partnership with PWNHealth represents an important step towards fulfilling our commitment to enhance and accelerate diagnostic testing by leveraging innovations in telehealth."

Financial and other terms of the agreement were not disclosed.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.